Page 34 - Read Online
P. 34

Merhi et al. J Cancer Metastasis Treat 2021;7:42  https://dx.doi.org/10.20517/2394-4722.2021.80  Page 13 of 16

               Ethical approval and consent to participate
               In line with the ethical tenets of the Declaration of Helsinki, all the patients diagnosed with AML provided
               their written and informed consent to participation in the study. Ethics approval was given by the
               independent ethics committees at Saint-Antoine Hospital (Paris, France) and the French National Institute
               of Cancer (“Tumorothèque Hématologie” Paris-Saint-Antoine Hospital COHO0203 INCA 2007). Control
               blood samples were collected from healthy, fully anonymized donors (no special written informed consent)
               in accordance with the institutional review boards of the Etablissement Français du Sang (Hôtel-Dieu
               Hospital, Paris, France) and the Institut National de la Santé et de la Recherche Médicale, Paris, France.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2021.


               REFERENCES
               1.       Testa U, Pelosi E, Castelli G. Endothelial progenitors in the tumor microenvironment. Adv Exp Med Biol 2020;1263:85-115.  DOI
                    PubMed
               2.       Ribatti D, Scavelli C, Roccaro AM, Crivellato E, Nico B, Vacca A. Hematopoietic cancer and angiogenesis. Stem Cells Dev
                    2004;13:484-95.  DOI  PubMed
               3.       Haouas H. Angiogenesis and acute myeloid leukemia. Hematology 2014;19:311-23.  DOI  PubMed
               4.       Najafabadi M, Shamsasenjan K, Akbarzadehalaleh P. Angiogenesis status in patients with acute myeloid leukemia: from diagnosis to
                    post-hematopoietic stem cell transplantation. Int J Organ Transplant Med 2017;8:57-67.  PubMed  PMC
               5.       Bertolini F, Mancuso P, Gobbi A, Pruneri G. The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol
                    2000;28:993-1000.  DOI  PubMed
               6.       Moehler TM, Neben K, Ho AD, Goldschmidt H. Angiogenesis in hematologic malignancies. Ann Hematol 2001;80:695-705.  DOI
                    PubMed
               7.       Rajkumar SV, Mesa RA, Tefferi A. A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies. J
                    Hematother Stem Cell Res 2002;11:33-47.  DOI  PubMed
               8.       Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and
                    relationship to tumor progression. Biochim Biophys Acta-Reviews on Cancer 2012;1825:29-36.  DOI  PubMed
               9.       Moss LA, Jensen-Taubman S, Stetler-Stevenson WG. Matrix metalloproteinases: changing roles in tumor progression and metastasis.
                    Am J Pathol 2012;181:1895-9.  DOI  PubMed  PMC
               10.       Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in
                    human diseases. Int J Mol Sci 2020:21.  DOI  PubMed  PMC
               11.       Murphy G, Nagase H. Localizing matrix metalloproteinase activities in the pericellular environment. Febs J 2010;278:2-15.  DOI
                    PubMed  PMC
               12.       Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011;41:271-90.  DOI  PubMed
                    PMC
               13.       Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular
                    formation and remodeling. Mediators Inflamm 2013;2013:928315.  DOI  PubMed  PMC
               14.       Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67.  DOI
                    PubMed  PMC
               15.       Medina MA, Martínez-Poveda B, Amores-Sánchez MI, Quesada AR. Hyperforin: more than an antidepressant bioactive compound?
                    Life Sci 2006;79:105-11.  DOI  PubMed
               16.       McGrowder DA, Miller FG, Nwokocha CR, et al. Medicinal herbs used in traditional management of breast cancer: mechanisms of
                    action. Medicines (Basel) 2020;7:47.  DOI  PubMed  PMC
               17.       Varghese R, Dalvi YB. Natural products as anticancer agents. Curr Drug Targets 2020.  DOI  PubMed
               18.       Park SH, Kim M, Lee S, Jung W, Kim B. Therapeutic potential of natural products in treatment of cervical cancer: a review.
                    Nutrients 2021;13:154.  DOI  PubMed  PMC
               19.       Quiney C, Billard C, Salanoubat C, Fourneron JD, Kolb JP. Hyperforin, a new lead compound against the progression of cancer and
                    leukemia? Leukemia 2006;20:1519-25.  DOI  PubMed
               20.       Borrelli F, Izzo AA. Herb-drug interactions with St John’s wort (Hypericum perforatum): an update on clinical observations. Aaps J
                    2009;11:710-27.  DOI  PubMed  PMC
               21.       Feisst C, Pergola C, Rakonjac M, et al. Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo. Cell Mol
                    Life Sci 2009;66:2759-71.  DOI  PubMed
               22.       Menegazzi M, Masiello P, Novelli M. Anti-tumor activity of hypericum perforatum L. and hyperforin through modulation of
   29   30   31   32   33   34   35   36   37   38   39